<DOC>
	<DOCNO>NCT02659657</DOCNO>
	<brief_summary>The effect haploidentical rhG-CSF-mobilized unmanipulated blood marrow transplantation ( HBMT ) hematological malignancy well established.The aim prospective cohort trial determine acute graft-versus-host disease ( aGVHD ) could decrease IL2 therapy post HBMT .</brief_summary>
	<brief_title>Prophylaxis Roles IL-2 Treatment Acute GVHD After Transplantation</brief_title>
	<detailed_description>The effect haploidentical rhG-CSF-mobilized unmanipulated blood marrow transplantation ( HBMT ) hematological malignancy well established.The aim prospective cohort trial determine acute graft-versus-host disease ( aGVHD ) could decrease IL2 therapy post HBMT.low dose IL-2 ( 40 million U/m2 ) administer WBC engraftment day 90 post haploidentical transplantation . IL-2 administer three time week .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . Aged 1565 year old 2 . Acute leukemia complete remission ( CR1/CR2 ) receive myeloablative haploidentical alloHSCT 3 . WBC engraftment ( ANC &gt; 500/ul continuous 3 day ) 4 . At least +7d 5 . Less equal +15d 6. non TALL 7. active IIIV aGVHD 8. severe infection 9 . Karnofsky score great equal 90 % 10 . Haploidentical donor sibling , child father 11 . Ensure informed consent sign faxed Research Coordinator 1 . Exposure clinical trial prior enrollment 2 . Active malignant disease relapse MRD positive 3 . Active , uncontrolled infection 4 . Inability comply IL2 treatment regimen 5 . Active , uncontrolled IIIV aGVHD 6 . Haploidentical donor mother collateral donor 7 . Clinical Signs severe pulmonary dysfunction 8 . Clinical Signs sever cardiac dysfunction 9 . Receiving corticosteroid GVHD treatment</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>